-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although antiretroviral therapy is very effective in suppressing HIV, the difficulty of taking the drug for life and the possibility of long-term side effects and the development of drug resistance have promoted the research of effective alternatives to daily antiretroviral drugs
.
In recent years, people have been seeking several treatment strategies to cure HIV infection
.
One such strategy is to eradicate the persistent HIV reservoir among infected people receiving antiretroviral therapy
Infect
Another approach is to develop immune- based therapies that aim to achieve maximum viral suppression in the absence of antiretroviral therapy, without necessarily eliminating persistent HIV reservoirs
.
In this regard, it has been shown that a small number of HIV-infected people start receiving antiretroviral therapy in the acute/early stage of infection, and the amount of virus in the plasma can be controlled for a long time after ATI (analytical treatment interruption)
immunity
A better understanding of the basic mechanisms of virus control in these people can provide inspiration for the development and application of new therapies
.
To this end, frequent and long-term comprehensive analysis of various immunological and virological parameters, as well as routine screening of secretly taking antiretroviral drugs and HIV super infection , can discover factors and factors that maintain virological remission of these people.
Screening
Recently, researchers conducted a long-term study on two HIV-infected people (No.
04 and No.
30) who previously participated in the placebo group of randomized, controlled therapeutic vaccine trials including ATI (ClinicalTrials.
gov identifier: NCT01859325 )
.
Systematic genetic analysis of plasma viremia level and HIV sequence after stopping antiretroviral therapy
.
.
Systematic genetic analysis of plasma viremia level and HIV sequence after stopping antiretroviral therapy
Management Over time, the virus continues to evolve and/or reactivate the pre-existing virus library As time goes by, the virus continues to evolve and/or reactivate the pre-existing virus library .
The importance of frequent monitoring of undisclosed ART use and super infection during the ATI phase The importance of frequent monitoring of undisclosed ART use and super infection during the ATI phase
Original source:
Original source:Jana Blazkova et al.
Jana Blazkova et al.
Leave a message here